-
Most Recent
Search Results
240 results for frx
Actavis Prescribes Profits via M&A and Generic Drugs
This specialty pharmaceutical company is consolidating its way into becoming a post-Affordable Care Act powerhouse.
No Payday In Sight for Alzheimer’s Drug Stocks
At best, the drugs on the market are stopgap measures. They can’t cure the disease.
Is it Time to Follow Ichan Out of Amgen — and Other Biotechs?
Investor Carl Ichan recently dumped several biotechs. However, Amgen’s sales are strong, and with other positives, it’s possible he cut bait too soon.
Johnson & Johnson, Forest Labs Will Make You Sick
Johnson & Johnson beat expectations but its profits were down; Forest Labs missed and has a plunging profit forecast. Investors should be wary of both…
2 Biotech Stocks to Buy After Earnings
Actavis (ACT) and Jazz Pharmaceuticals (JAZZ) reported outstanding Q3 earnings and are strong biotech stocks to buy.
Wall Street’s 10 Biggest Deals of Q1 2014
The year is off to a hot start for M&A, as Facebook, Google, IBM and others got busy pulling off Q1’s biggest deals.
3 Mutual Funds Poised to Profit From Obamacare
By Bill Wysor — There are winners and losers in the changing healthcare industry, but let seasoned mutual fund managers do the legwork for you.
Buy Icahn Enterprises to Play Apple Stock with Less Risk
For a low-risk way to play a bounce back in Apple stock, let Carl Icahn and a bet on Icahn Enterprises stock lead the way.
4 Best Mutual Funds at Vanguard Now
Here are four of the top mutual fund investments from Vanguard now.
History Says Silver’s Next Move Could Be Explosive
Silver is as “good as gold.” Actually, it’s a better buy than gold right now. That’s not my opinion. It’s the “opinion” of an ancient…
Celebrity SPAC Merger News: 10 Stars Jumping on the SPAC Bandwagon
Investors should follow the latest celebrity SPAC merger news to see where money is moving. Here’s some of the top stars in the game.
Will 2014’s Top Performers Keep Performing?
These three stocks are likely to run higher, given both valuation and business environment.
What To Make Of Tuesday’s Surprising Market Move
Wall Street clearly made up for the shortened trading week with a broad rally on Tuesday. Here’s our new research on 50 stocks in Portfolio…
Maintain Realistic Expectations
The most that can be expected is a small rally and more sideways movement.
3 Funds to Play the Healthcare Megatrend
Healthcare has been hot in 2013, but more importantly, it’s set up to be a huge mover going forward thanks to several big trends. Here’s…
Stock Downgrades: BAC, BA, PC, TM
Bank of America (BAC), Boeing (BA), Panasonic (PC) and Toyota (TM) were among some of the widely held stocks downgraded by Louis Navellier in his…
Say Hello to the $400 Billion AI Bazooka Aimed at the Market
The loudest voices in the market are currently the doubters, warning that the tech rally has gone too far. But they’re missing the single most…
Trade of the Day: Teva Pharmaceuticals (TEVA) and Mylan (MYL)
Recent price shocks in biotech stocks is a good example of the risks investors may be exposed to as healthcare continues to become more complicated.
Alzheimer’s Stocks Are a Stealth Opportunity
Alzheimer’s stocks could mean huge rewards for investors, but as always, you have to pick the right ones. Here are three with solid prospects.
75 Stock Ratings to Stay Ahead of the Eight Ball
Many investors take a break from the market during the summer. By doing so, they miss out on important trends. Here are 75 stock ratings…
7 – 10 of 240 results
